dromlakhani Administer progestin challenge to assess outflow tract integrity and estrogen exposure
STEP 1 — Gather Information
Confirm pregnancy exclusion with a negative urine or serum hCG test, document duration and pattern of amenorrhea, review medical history for contraindications (e.g., undiagnosed vaginal bleeding, known outflow tract anomaly), and list current medications. Action: Obtain pregnancy test and baseline clinical history before proceeding.
STEP 2 — Rule In / Rule Out
Administer a progestin regimen (e.g., medroxyprogesterone acetate 10 mg orally daily for 10 days, norethindrone acetate 5 mg daily for 5–10 days, or micronized progesterone 200–300 mg daily for 10 days) and monitor for withdrawal bleeding within one week after the final dose. Decision: If bleeding occurs, rule in adequate estrogen exposure and a patent outflow tract; if no bleeding occurs, rule out adequate estrogen exposure or suspect outflow tract obstruction.
STEP 3 — Classify or Stratify
In the absence of withdrawal bleeding, perform a pelvic ultrasound to measure endometrial thickness and evaluate for Müllerian tract anomalies; consider obtaining a serum estradiol level and, if endometrium is thin (<5 mm), repeat the progestin challenge after estrogen priming (e.g., conjugated equine estrogen 0.625 mg daily for 25 days). Action: Perform ultrasound and assess endometrial thickness.
STEP 4 — Decide
If withdrawal bleeding is present, reassure adequate estrogen exposure and outflow tract integrity, then continue FHA management focused on correcting energy imbalance (nutrition, exercise, stress reduction). If bleeding is absent and ultrasound shows endometrium <5 mm, consider low estrogen exposure and initiate low‑dose estrogen therapy; if bleeding is absent with endometrium ≥5 mm, suspect outflow tract obstruction and pursue hysteroscopy or pelvic MRI for further evaluation. Action: Initiate the appropriate next step based on findings.
Clinical Guardrails / Mimics / Pitfalls
Do not interpret withdrawal bleeding as proof of ovulation or sufficient for conception; avoid the challenge in pregnancy; do not rely solely on the test to diagnose FHA (it is a diagnosis of exclusion); be aware of progestin side effects (bloating, breast tenderness, mood changes) and poor tolerance in some patients; do not use the challenge in patients with known androgen excess or PCOS without considering overlapping pathology; do not administer if undiagnosed abnormal uterine bleeding is present.
Concrete Clinical Example
A 22‑year‑old woman presents with 6 months of amenorrhea, BMI 17 kg/m², and a negative urine pregnancy test. She receives medroxyprogesterone acetate 10 mg daily for 10 days. Three days after the last pill she experiences light spotting progressing to moderate bleeding lasting 4 days. This withdrawal bleed indicates adequate estrogen exposure and an intact outflow tract, allowing the clinician to focus on correcting energy imbalance.
Source: Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, doi:10.1210/jc.2017-00131